Sengenics, the functional proteomics company, today announced the retail product launch of two new protein microarrays, the IMMUNOME™ v4 Discovery Array and the CTA Array which are now available for purchase for the very first time by any researcher. Both these arrays use the patented Sengenics KREX™ functional proteomics technology that ensures that only correctly folded, functional proteins are immobilised to the microarray surface.
Johan Poole-Johnson, Chief Commercial Officer of Sengenics said, “We are seeing a significant market demand for our KREX™-based arrays in disease areas that are not in Sengenics’ core discovery pipeline. We have therefore decided to give access to these two new arrays to the wider research community without necessarily entering into a formal collaboration.”
The IMMUNOME™ v4 Discovery Array contains only full-length, correctly folded and functional human proteins, spotted in quadruplicate. The array has a wide breadth of applications for discovery of diagnostic, prognostic and protective autoantibodies. The same array can also serve as a platform to discover protein-protein, protein-DNA or protein-RNA interactions.
The CTA Array is also a KREX™-based protein array for high-throughput quantification of autoantibodies to Cancer-Testis (CT) Antigens. CT antigens are a group of unrelated proteins that show highly restricted expression profiles in adult somatic tissues but which are aberrantly expressed in various cancers. The key application of the array is for unique differential profiling of cancer-antigens in various cancer types. The CTA Array can also be used to monitor patient responses in checkpoint inhibitor studies, determine epitope recognition in patients or monitor patients in experimental cancer vaccine studies.
Both the IMMUNOME™ v4 Discovery Array and CTA Array are available for direct purchase from the Sengenics website, scienceexchange.com, selectscience.com and Sengenics distributors around the world.
Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ is a patented proteomics technology which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge. The three key applications of the KREX™ technology are; discovery of autoantibody biomarkers for human diseases, autoantibody-based immunotoxicity profiling of cancer immunotherapy patients and pharmaceutical industry-specific applications such as high-throughput SAR screening, predictive toxicology and antibody generation using KREX™ proteins.